Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaxis Ltd ( (AU:SNT) ) has shared an announcement.
Syntara Limited announced positive top-line results from its Phase 2a clinical trial of amsulostat in combination with ruxolitinib for treating myelofibrosis. The trial demonstrated that amsulostat is safe and well-tolerated, with significant improvements in symptom scores and spleen volume reductions sustained over 52 weeks. These results highlight amsulostat’s competitive profile and potential as a novel therapy for patients with high disease burden. The findings support further clinical development and partnership opportunities, with strategic advisors appointed to guide the next steps.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company focused on developing treatments for myelofibrosis, a type of bone marrow cancer. The company is engaged in advancing its drug candidates through clinical trials to address unmet medical needs in this area.
Average Trading Volume: 4,424,039
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
See more insights into SNT stock on TipRanks’ Stock Analysis page.